Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG by Jessica | Apr 16, 2025 Read more »
SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for the Non-Opioid Treatment of Pain by Jessica | Feb 4, 2025 Read more »
Quibim Announces $50 Million in Series A Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers by Jessica | Jan 28, 2025 Read more »
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis by Jessica | Dec 19, 2024 Read more »
SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-opioid Treatments for Pain by Jessica | Dec 18, 2024 Read more »
